Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 527

1.

Pathophysiology of Tumor Cell Release into the Circulation and Characterization of CTC.

Todenhöfer T, Pantel K, Stenzl A, Werner S.

Recent Results Cancer Res. 2020;215:3-24. doi: 10.1007/978-3-030-26439-0_1.

PMID:
31605221
2.

Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer.

Joosse SA, Beyer B, Gasch C, Nastały P, Kuske A, Isbarn H, Horst LJ, Hille C, Gorges TM, Cayrefourcq L, Alix-Panabières C, Tennstedt P, Riethdorf S, Schlomm T, Pantel K.

Clin Chem. 2019 Oct 10. pii: clinchem.2019.310912. doi: 10.1373/clinchem.2019.310912. [Epub ahead of print]

PMID:
31601564
3.

Epithelial keratins: Biology and implications as diagnostic markers for liquid biopsies.

Werner S, Keller L, Pantel K.

Mol Aspects Med. 2019 Sep 25. pii: S0098-2997(19)30057-3. doi: 10.1016/j.mam.2019.09.001. [Epub ahead of print] Review.

PMID:
31563278
4.

Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer.

Hille C, Gorges TM, Riethdorf S, Mazel M, Steuber T, Amsberg GV, König F, Peine S, Alix-Panabières C, Pantel K.

Cells. 2019 Sep 11;8(9). pii: E1067. doi: 10.3390/cells8091067.

5.

Clonality of circulating tumor cells in breast cancer brain metastasis patients.

Riebensahm C, Joosse SA, Mohme M, Hanssen A, Matschke J, Goy Y, Witzel I, Lamszus K, Kropidlowski J, Petersen C, Kolb-Kokocinski A, Sauer S, Borgmann K, Glatzel M, Müller V, Westphal M, Riethdorf S, Pantel K, Wikman H.

Breast Cancer Res. 2019 Sep 3;21(1):101. doi: 10.1186/s13058-019-1184-2.

6.

Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells.

Keller L, Pantel K.

Nat Rev Cancer. 2019 Oct;19(10):553-567. doi: 10.1038/s41568-019-0180-2. Epub 2019 Aug 27. Review.

PMID:
31455893
7.

Circulating Tumor Cells in Head and Neck Carcinomas.

Pantel K.

Clin Chem. 2019 Oct;65(10):1193-1195. doi: 10.1373/clinchem.2019.309609. Epub 2019 Aug 6. No abstract available.

PMID:
31387888
8.

In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy.

Chen S, Tauber G, Langsenlehner T, Schmölzer LM, Pötscher M, Riethdorf S, Kuske A, Leitinger G, Kashofer K, Czyż ZT, Polzer B, Pantel K, Sedlmayr P, Kroneis T, El-Heliebi A.

Cancers (Basel). 2019 Jul 3;11(7). pii: E933. doi: 10.3390/cancers11070933.

9.

EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer.

Lindsay CR, Blackhall FH, Carmel A, Fernandez-Gutierrez F, Gazzaniga P, Groen HJM, Hiltermann TJN, Krebs MG, Loges S, López-López R, Muinelo-Romay L, Pantel K, Priest L, Riethdorf S, Rossi E, Terstappen L, Wikman H, Soria JC, Farace F, Renehan A, Dive C, Besse B, Michiels S.

Eur J Cancer. 2019 Aug;117:60-68. doi: 10.1016/j.ejca.2019.04.019. Epub 2019 Jun 27.

10.

Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?

Hofman P, Heeke S, Alix-Panabières C, Pantel K.

Ann Oncol. 2019 Sep 1;30(9):1448-1459. doi: 10.1093/annonc/mdz196.

PMID:
31228184
11.

Biology and clinical relevance of EpCAM.

Keller L, Werner S, Pantel K.

Cell Stress. 2019 May 21;3(6):165-180. doi: 10.15698/cst2019.06.188. Review.

12.

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors.

Janning M, Kobus F, Babayan A, Wikman H, Velthaus JL, Bergmann S, Schatz S, Falk M, Berger LA, Böttcher LM, Päsler S, Gorges TM, O'Flaherty L, Hille C, Joosse SA, Simon R, Tiemann M, Bokemeyer C, Reck M, Riethdorf S, Pantel K, Loges S.

Cancers (Basel). 2019 Jun 17;11(6). pii: E835. doi: 10.3390/cancers11060835.

13.

Prospective Comparison of the Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of a Single Patient's Cohort With Esophageal Cancer.

Konczalla L, Ghadban T, Effenberger KE, Wöstemeier A, Riethdorf S, Uzunoglu FG, Izbicki JR, Pantel K, Bockhorn M, Reeh M.

Ann Surg. 2019 Jun 7. doi: 10.1097/SLA.0000000000003406. [Epub ahead of print]

PMID:
31188197
14.

Response to Di Cosimo, Torri, and Porcu.

Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, deGregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C.

J Natl Cancer Inst. 2019 Jun 11. pii: djz095. doi: 10.1093/jnci/djz095. [Epub ahead of print] No abstract available.

PMID:
31187135
15.

Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays.

Budna-Tukan J, Świerczewska M, Mazel M, Cieślikowski WA, Ida A, Jankowiak A, Antczak A, Nowicki M, Pantel K, Azria D, Zabel M, Alix-Panabières C.

Cancers (Basel). 2019 Jun 10;11(6). pii: E802. doi: 10.3390/cancers11060802.

16.

Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial.

Mandel PC, Huland H, Tiebel A, Haese A, Salomon G, Budäus L, Tilki D, Chun F, Heinzer H, Graefen M, Pantel K, Riethdorf S, Steuber T.

Eur Urol Focus. 2019 Jun 6. pii: S2405-4569(19)30145-2. doi: 10.1016/j.euf.2019.05.008. [Epub ahead of print]

PMID:
31178293
17.

EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients.

Scharpenseel H, Hanssen A, Loges S, Mohme M, Bernreuther C, Peine S, Lamszus K, Goy Y, Petersen C, Westphal M, Glatzel M, Riethdorf S, Pantel K, Wikman H.

Sci Rep. 2019 May 15;9(1):7406. doi: 10.1038/s41598-019-43678-6.

18.

Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours.

Ricklefs FL, Maire CL, Reimer R, Dührsen L, Kolbe K, Holz M, Schneider E, Rissiek A, Babayan A, Hille C, Pantel K, Krasemann S, Glatzel M, Heiland DH, Flitsch J, Martens T, Schmidt NO, Peine S, Breakefield XO, Lawler S, Chiocca EA, Fehse B, Giebel B, Görgens A, Westphal M, Lamszus K.

J Extracell Vesicles. 2019 Mar 21;8(1):1588555. doi: 10.1080/20013078.2019.1588555. eCollection 2019.

19.

Characterization of circulating DNA in plasma of patients after allogeneic bone grafting.

Solakoglu Ö, Steinbach B, Götz W, Heydecke G, Pantel K, Schwarzenbach H.

Clin Oral Investig. 2019 Mar 3. doi: 10.1007/s00784-019-02867-3. [Epub ahead of print]

PMID:
30826920
20.

Interplay of lncRNA H19/miR-675 and lncRNA NEAT1/miR-204 in breast cancer.

Müller V, Oliveira-Ferrer L, Steinbach B, Pantel K, Schwarzenbach H.

Mol Oncol. 2019 May;13(5):1137-1149. doi: 10.1002/1878-0261.12472. Epub 2019 Mar 14.

21.

Liquid biopsy and minimal residual disease - latest advances and implications for cure.

Pantel K, Alix-Panabières C.

Nat Rev Clin Oncol. 2019 Jul;16(7):409-424. doi: 10.1038/s41571-019-0187-3. Review.

PMID:
30796368
22.

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.

Banys-Paluchowski M, Witzel I, Aktas B, Fasching PA, Hartkopf A, Janni W, Kasimir-Bauer S, Pantel K, Schön G, Rack B, Riethdorf S, Solomayer EF, Fehm T, Müller V.

Sci Rep. 2019 Feb 19;9(1):2318. doi: 10.1038/s41598-018-37259-2.

23.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K.

Crit Rev Oncol Hematol. 2019 Feb;134:39-45. doi: 10.1016/j.critrevonc.2018.12.004. Epub 2018 Dec 19. Review.

PMID:
30771872
24.

Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial.

Janning M, Müller V, Vettorazzi E, Cubas-Cordova M, Gensch V, Ben-Batalla I, Zu Eulenburg C, Schem C, Fasching PA, Schnappauf B, Karn T, Fehm T, Just M, Kühn T, Holms F, Overkamp F, Krabisch P, Rack B, Denkert C, Untch M, Tesch H, Rezai M, Kittel K, Pantel K, Bokemeyer C, Loibl S, von Minckwitz G, Loges S.

Int J Cancer. 2019 Aug 1;145(3):857-868. doi: 10.1002/ijc.32163. Epub 2019 Mar 4.

PMID:
30694523
25.

Detection and Characterization of Circulating Tumor Cells in Patients with Merkel Cell Carcinoma.

Riethdorf S, Hildebrandt L, Heinzerling L, Heitzer E, Fischer N, Bergmann S, Mauermann O, Waldispühl-Geigl J, Coith C, Schön G, Peine S, Schuler G, Speicher MR, Moll I, Pantel K.

Clin Chem. 2019 Mar;65(3):462-472. doi: 10.1373/clinchem.2018.297028. Epub 2019 Jan 9.

PMID:
30626636
26.

Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility.

Pantel K, Hille C, Scher HI.

Clin Chem. 2019 Jan;65(1):87-99. doi: 10.1373/clinchem.2018.287102. Review.

PMID:
30602476
27.

Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease.

Hanssen A, Riebensahm C, Mohme M, Joosse SA, Velthaus JL, Berger LA, Bernreuther C, Glatzel M, Loges S, Lamszus K, Westphal M, Riethdorf S, Pantel K, Wikman H.

Cancers (Basel). 2018 Dec 19;10(12). pii: E527. doi: 10.3390/cancers10120527.

28.

Development and Characterization of a Spontaneously Metastatic Patient-Derived Xenograft Model of Human Prostate Cancer.

Lange T, Oh-Hohenhorst SJ, Joosse SA, Pantel K, Hahn O, Gosau T, Dyshlovoy SA, Wellbrock J, Feldhaus S, Maar H, Gehrcke R, Kluth M, Simon R, Schlomm T, Huland H, Schumacher U.

Sci Rep. 2018 Dec 3;8(1):17535. doi: 10.1038/s41598-018-35695-8.

29.

Liquid biopsy: novel technologies and clinical applications.

Reimers N, Pantel K.

Clin Chem Lab Med. 2019 Feb 25;57(3):312-316. doi: 10.1515/cclm-2018-0610.

30.

Liquid biopsies.

Lianidou E, Pantel K.

Genes Chromosomes Cancer. 2019 Apr;58(4):219-232. doi: 10.1002/gcc.22695. Review.

PMID:
30382599
31.

Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes.

Soler A, Cayrefourcq L, Mazard T, Babayan A, Lamy PJ, Assou S, Assenat E, Pantel K, Alix-Panabières C.

Sci Rep. 2018 Oct 29;8(1):15931. doi: 10.1038/s41598-018-34365-z.

32.

Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.

Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C; SUCCESS Study Group.

J Natl Cancer Inst. 2019 Apr 1;111(4):380-387. doi: 10.1093/jnci/djy152.

PMID:
30312434
33.

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.

Stevic I, Müller V, Weber K, Fasching PA, Karn T, Marmé F, Schem C, Stickeler E, Denkert C, van Mackelenbergh M, Salat C, Schneeweiss A, Pantel K, Loibl S, Untch M, Schwarzenbach H.

BMC Med. 2018 Oct 10;16(1):179. doi: 10.1186/s12916-018-1163-y.

34.

ALDH1-positive intratumoral stromal cells indicate differentiated epithelial-like phenotype and good prognosis in prostate cancer.

Nastały P, Filipska M, Morrissey C, Eltze E, Semjonow A, Brandt B, Pantel K, Bednarz-Knoll N.

Transl Res. 2019 Jan;203:49-56. doi: 10.1016/j.trsl.2018.08.007. Epub 2018 Sep 12.

PMID:
30287243
35.

Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer.

Jauch SF, Riethdorf S, Sprick MR, Schütz F, Schönfisch B, Brucker SY, Deutsch TM, Nees J, Saini M, Becker LM, Burwinkel B, Sinn P, Marmé F, Pantel K, Jäger D, Sohn C, Trumpp A, Wallwiener M, Schneeweiss A.

Breast Cancer Res Treat. 2019 Jan;173(1):155-165. doi: 10.1007/s10549-018-4972-y. Epub 2018 Oct 1.

PMID:
30276763
36.

Absence of HER2 Expression of Circulating Tumor Cells in Patients with Non-Metastatic Esophageal Cancer.

Woestemeier A, Ghadban T, Riethdorf S, Harms-Effenberger K, Konczalla L, Uzunoglu FG, Izbicki JR, Pantel K, Bockhorn M, Reeh M.

Anticancer Res. 2018 Oct;38(10):5665-5669. doi: 10.21873/anticanres.12902.

PMID:
30275185
37.

Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR, and tumor progression in prostate cancer.

Omari A, Nastały P, Stoupiec S, Bałabas A, Dąbrowska M, Bielińska B, Huss S, Pantel K, Semjonow A, Eltze E, Brandt B, Bednarz-Knoll N.

Int J Cancer. 2019 Feb 1;144(3):607-614. doi: 10.1002/ijc.31905. Epub 2018 Oct 22.

PMID:
30265376
38.

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.

Berger LA, Janning M, Velthaus JL, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S.

J Thorac Oncol. 2018 Dec;13(12):e243-e246. doi: 10.1016/j.jtho.2018.08.2025. Epub 2018 Sep 8. No abstract available.

PMID:
30205165
39.

Different signatures of miR-16, miR-30b and miR-93 in exosomes from breast cancer and DCIS patients.

Ni Q, Stevic I, Pan C, Müller V, Oliviera-Ferrer L, Pantel K, Schwarzenbach H.

Sci Rep. 2018 Aug 28;8(1):12974. doi: 10.1038/s41598-018-31108-y.

40.

Exosomal microRNAs as tumor markers in epithelial ovarian cancer.

Pan C, Stevic I, Müller V, Ni Q, Oliveira-Ferrer L, Pantel K, Schwarzenbach H.

Mol Oncol. 2018 Nov;12(11):1935-1948. doi: 10.1002/1878-0261.12371. Epub 2018 Oct 9.

41.

Clinical relevance of cytoskeleton associated proteins for ovarian cancer.

Schiewek J, Schumacher U, Lange T, Joosse SA, Wikman H, Pantel K, Mikhaylova M, Kneussel M, Linder S, Schmalfeldt B, Oliveira-Ferrer L, Windhorst S.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2195-2205. doi: 10.1007/s00432-018-2710-9. Epub 2018 Aug 9.

PMID:
30094535
42.

miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry, and Bone Destruction by Directly Targeting Multiple Bone Metastasis-Associated Genes.

Croset M, Pantano F, Kan CWS, Bonnelye E, Descotes F, Alix-Panabières C, Lecellier CH, Bachelier R, Allioli N, Hong SS, Bartkowiak K, Pantel K, Clézardin P.

Cancer Res. 2018 Sep 15;78(18):5259-5273. doi: 10.1158/0008-5472.CAN-17-3058. Epub 2018 Jul 24.

43.

Chromosomal Aberrations Associated with Sequential Steps of the Metastatic Cascade in Colorectal Cancer Patients.

Joosse SA, Souche FR, Babayan A, Gasch C, Kerkhoven RM, Ramos J, Fabre JM, Riethdorf S, König A, Wikman H, Alix-Panabières C, Pantel K.

Clin Chem. 2018 Oct;64(10):1505-1512. doi: 10.1373/clinchem.2018.289819. Epub 2018 Jul 20.

44.

Abstracts from the 11th International Symposium on Minimal Residual Disease, 3-5 May 2018, Montpellier, France.

Alix-Panabières C, Pantel K.

Clin Exp Metastasis. 2018 Mar;35(3):167-217. doi: 10.1007/s10585-018-9911-0. No abstract available.

PMID:
30008067
45.

The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer.

Banys-Paluchowski M, Witzel I, Riethdorf S, Pantel K, Rack B, Janni W, Fasching PA, Aktas B, Kasimir-Bauer S, Hartkopf A, Solomayer EF, Fehm T, Müller V.

Breast Cancer Res Treat. 2018 Nov;172(1):93-104. doi: 10.1007/s10549-018-4882-z. Epub 2018 Jul 12.

PMID:
30003393
46.

11th International Symposium on Minimal Residual Cancer (ISMRC): 3-5 May 2018, Montpellier, France.

Alix-Panabières C, Pantel K.

Clin Exp Metastasis. 2018 Mar;35(3):87-90. doi: 10.1007/s10585-018-9909-7. Epub 2018 Jul 6. No abstract available.

PMID:
29980892
47.

Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment.

Bauer ECA, Schochter F, Widschwendter P, DeGregorio A, Andergassen U, Friedl TWP, Fasching PA, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Janni W, Rack B, Scholz C; SUCCESS Study Group.

Breast Cancer Res Treat. 2018 Oct;171(3):571-580. doi: 10.1007/s10549-018-4856-1. Epub 2018 Jun 21.

PMID:
29931425
48.

Inverse Perfusion Requirements of Supra- and Infratentorial Brain Metastases Formation.

Schneider T, Kemmling A, Schroeder J, Pantel K, Glatzel M, Schoen G, Mohme M, Fiehler J, Gellißen S.

Front Neurol. 2018 May 30;9:391. doi: 10.3389/fneur.2018.00391. eCollection 2018.

49.

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.

Ignatiadis M, Litière S, Rothe F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching PA, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart M, Sotiriou C, Rack B, Pierga JY.

Ann Oncol. 2018 Aug 1;29(8):1777-1783. doi: 10.1093/annonc/mdy211.

PMID:
29893791
50.

Intraoperative detection of circulating tumor cells in pulmonary venous blood during metastasectomy for colorectal lung metastases.

Le UT, Bronsert P, Picardo F, Riethdorf S, Haager B, Rylski B, Czerny M, Beyersdorf F, Wiesemann S, Pantel K, Passlick B, Kaifi JT, Schmid S.

Sci Rep. 2018 Jun 8;8(1):8751. doi: 10.1038/s41598-018-26410-8.

Supplemental Content

Loading ...
Support Center